SWOG S2001

Official Title

A testing the addition of pembrolizumab, an immunotherapy cancer drug to olaparib alone as therapy for patients with pancreatic cancer that has spread with unhealthy tumor suppressor genes.

Study Purpose

To compare the usual treatment alone to using pembrolizumab plus the usual treatment.

Diagnosis

Patients who have pancreatic cancer with a germline BRCA1 or BRCA2 gene mutation that has spread to other parts of your body.

Eligibility

Patient must have a histologic or cytologic diagnosis of pancreatic adenocarcinoma.

Patient must have metastatic disease and receive first line platinum-based chemotherapy.

Patients must have had a CT or MRI showing stable or responding disease on first line platinum-based chemotherapy.

No neuroendocrine, acinar cell, or adenosquamous.

Patients must have BRCA 1 or 2 mutation.

Patient must have metastatic disease and received first line platinum-based chemotherapy

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

• Group l: Patients will receive olaparib plus the study drug pembrolizumab.  Olaparib will be taken during the pembrolizumab infusion.

• Group 2: Patients will receive olaparib only.